Neurocrine Biosciences Inc. (Nasdaq: NBIX) reported that its tardive dyskinesia treatment NBI-98854 failed a Phase IIb Kinect study sending the stock price plummeting $4.88 to $11.82.
Disappointing Test Results For Neurocrine Biosciences
September 10, 2013 at 07:50 AM EDT
